Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Hodgkin Lymphoma and T/NK Cell Lymphoma Hodgkin Lymphoma and T/NK Cell Lymphoma

624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma

Watch Session

470 Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, et al.

 

471 Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, et al.

 

472 Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Alex F. Herrera, Lu Chen, Yago Nieto, et al.

 

473 Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, Stefan K. Barta, Daniel J. Landsburg, et al.

 

474 Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, Carmelo Carlo-Stella, Graham P. Collins, et al.

 

475 PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study according to ASH clinically relevant abstract

Olivier Casasnovas, Judith Racape, Julie Dechene, et al.